title: Short- and long-term effect of sitagliptin after near normalization of glycemic control with insulin in poorly controlled Japanese type 2 diabetic patients.
abstract: OBJECTIVE
  The aim of the present study was to examine the short- and long-term effect of sitagliptin on glucose tolerance after near normalization of glycemic control with insulin in poorly controlled type 2 diabetic patients.
  
  
  METHODS
  We consecutively enrolled a total of 30 type 2 diabetic patients whose glycated hemoglobin levels (National Glycohemoglobin Standardization Program) were ≥7.4%, stopped all oral antidiabetic drugs and started insulin therapy. When fasting plasma glucose levels became <140 mg/dL, we carried out the first oral glucose tolerance test (OGTT). After 1-week sitagliptin treatment (50 mg/day), the second OGTT was carried out. Furthermore, we evaluated the long-term efficacy of sitagliptin on glucose tolerance after near normalization of glycemic control with insulin.
  
  
  RESULTS
  After 1-week sitagliptin treatment, the area under the curve of insulin was markedly increased, and the area under the curve of glucagon and glucose was markedly decreased. Duration of diabetes and insulin secretory capacity were correlated with the effect of sitagliptin. Furthermore, interestingly, near normalization of glycemic control with insulin therapy for 1-2 weeks brought out the long-term effectiveness of sitagliptin on glucose tolerance for 24 weeks, which was not observed with other antidiabetic drugs.
  
  
  CONCLUSIONS
  These findings suggest that near normalization of glycemic control with insulin improves the clinical response to sitagliptin in poorly controlled type 2 diabetic patients.
authors.affiliation: Department of Metabolic Medicine Osaka University Graduate School of Medicine Osaka Japan.
authors.forename: Keiko
authors.initials: K
authors.lastname: Fujisawa
authors.affiliation: Department of Metabolic Medicine Osaka University Graduate School of Medicine Osaka Japan.
authors.forename: Tetsuyuki
authors.initials: T
authors.lastname: Yasuda
authors.affiliation: Department of Metabolic Medicine Osaka University Graduate School of Medicine Osaka Japan.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kaneto
authors.affiliation: Department of Metabolic Medicine Osaka University Graduate School of Medicine Osaka Japan.
authors.forename: Naoto
authors.initials: N
authors.lastname: Katakami
authors.affiliation: Department of Metabolic Medicine Osaka University Graduate School of Medicine Osaka Japan.
authors.forename: Mayumi
authors.initials: M
authors.lastname: Tsuji
authors.affiliation: Department of Metabolic Medicine Osaka University Graduate School of Medicine Osaka Japan.
authors.forename: Fumiyo
authors.initials: F
authors.lastname: Kubo
authors.affiliation: Department of Metabolic Medicine Osaka University Graduate School of Medicine Osaka Japan.
authors.forename: Shugo
authors.initials: S
authors.lastname: Sasaki
authors.affiliation: Department of Metabolic Medicine Osaka University Graduate School of Medicine Osaka Japan.
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Miyashita
authors.affiliation: Department of Metabolic Medicine Osaka University Graduate School of Medicine Osaka Japan.
authors.forename: Toyoko
authors.initials: T
authors.lastname: Naka
authors.affiliation: Department of Metabolic Medicine Osaka University Graduate School of Medicine Osaka Japan.
authors.forename: Ryuuichi
authors.initials: R
authors.lastname: Kasami
authors.affiliation: Diabetes Therapeutics and Research Center Tokushima University Tokushima Japan.
authors.forename: Akio
authors.initials: A
authors.lastname: Kuroda
authors.affiliation: Diabetes Therapeutics and Research Center Tokushima University Tokushima Japan.
authors.forename: Munehide
authors.initials: M
authors.lastname: Matsuhisa
authors.affiliation: Department of Metabolic Medicine Osaka University Graduate School of Medicine Osaka Japan.
authors.forename: Iichiro
authors.initials: I
authors.lastname: Shimomura
keywords: Dipeptidyl peptidase‐4 inhibitor; Insulin therapy; Sitagliptin